Targeting EGFR T790M in NSCLC

Speaker: Pilar Garrido

P. Garrido discusses resistance to EGFR inhibitors, in particular T790M resistance mutation. She discusses techniques for capturing the resistance mutations in cases when the possibility of biopsy is limited, especially the convenience of circulating tumour DNA. She elaborates the updates from clinical studies with osimertinib in different settings of NSCLC, as presented at ELCC 2016.

Discussion Points

  • T790M and clinical relevance in NSCLC
  • Drugs that target T790M and approval status
  • How to capture T790M: companion diagnostics and new technologies
  • Highlights from osimertinib studies presented at ELCC 2016 (LBA1, LBA2)